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Cancer is a heterogeneous and complex genetic disease.
In addition to genetic mutations in oncogenes and
tumour suppressors, the onset and progression of cancer
is also bound to the cancer cell’s microenvironment.
After many years of ostracism the energetic metabolism
of cancer [1] has been accepted as an additional hall-
mark of the cancer phenotype [2] and mitochondrial/
glycolytic studies have spurred in the field. In this
regard, it has been reported that the relative expression
of b-F1-ATPase, which is the catalytic subunit of the
mitochondrial H+-ATP synthase and thus a rate-limiting
component of mitochondrial oxidative phosphorylation,
is significantly diminished in human tumours when
compared to its expression in normal tissues [2]. The
down-regulation of b-F1-ATPase is accompanied by an
increased expression of GAPDH, a marker of glycolysis.
The tumour drop in the b-F1-ATPase/GAPDH ratio,
that defines the “bioenergetic signature” of the cell [3], is
a phenotypic trait fulfilled by more than 95% of the car-
cinomas analyzed in large cohorts of breast, colon and
lung cancer patients [2]. These findings support a deficit
in the overall bioenergetic activity of mitochondria in
cancer. The quantification of the bioenergetic signature
in different human carcinomas revealed that, irrespective
of the cancer type, energy metabolism has a unique pro-
tein signature [4], thus providing a generic marker of
the cancer cell that might be exploited in the combat of
the disease [2]. The bioenergetic signature also has clini-
cal relevance as an indicator of disease progression and
as a predictive marker of the cellular response to che-
motherapy [2]. Moreover, the bioenergetic signature
affords a gauge of the glycolytic activity of the tumours,
supporting that an altered oxidative phosphorylation is
one of the determinants that underlies the abnormal
aerobic glycolysis of the cancer cell [5].
The specific repression of b-F1-ATPase mRNA trans-
lation partially explains the abnormal bioenergetic activ-
ity of mitochondria in colon, lung and breast tumours
[6] as well as in hepatocarcinomas [7]. By manipulation
of the bioenergetic signature in cancer cells we have
documented that tumour promotion inevitably requires
the selection of cells with a repressed bioenergetic activ-
ity of mitochondria [8]. In others words, cancer cells
with a functional bioenergetic activity of mitochondria
are unable to promote tumour development. In this pre-
sentation, I will summarize some of the findings that
stress that cancer progression requires the silencing of
the bioenergetic activity of mitochondria, emphasize its
potential value for translation to the bed-side and
discuss some of the strategies that we are developing
aimed at identifying the players that participate in the
regulation of the bioenergetic signature of the cancer
cell.
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